Literature DB >> 24280875

Risk matrix for prediction of advanced disease in a population-based study of patients with Crohn's Disease (the IBSEN Study).

Inger C Solberg1, Milada Cvancarova, Morten H Vatn, Bjørn Moum.   

Abstract

BACKGROUND: Identifying patients with Crohn's disease with increased risk of subsequent complications is essential for appropriate treatment. Based on exploratory analysis, we developed a prediction model for assessing the probability of developing advanced disease 5 and 10 years after diagnosis.
METHODS: A population-based cohort of 237 patients with Crohn's disease diagnosed from 1990-1994 was followed for 10 years. In the 5-year analysis, advanced disease was defined as having intestinal resection, progression in disease behavior, or need for thiopurines. The analysis was limited to patients with uncomplicated disease at diagnosis who were alive (n = 140), excluding those who were lost during follow-up (n = 8). For the 10-year analysis, advanced disease was defined as having surgery, excluding those who had surgery within the first 30 days (n = 7), those who died (n = 18), or were lost during follow-up (n = 22). Based on the best fitted multiple model, the probabilities of advanced disease were computed for selected baseline levels of the covariates and the results were arranged in a prediction matrix. Except for ASCA, all predictors were measured at diagnosis.
RESULTS: ASCA status, disease location, age, and need for systemic steroids were included in the 5-year prediction matrix. The probabilities of advanced disease during this period varied from 8.6% to 92.0% depending on the combination of predictors. The 10-year matrix combined ASCA status, disease behavior, age, and need for systemic steroids; the probabilities of advanced disease ranged from 12.4% to 96.7%.
CONCLUSIONS: Our prediction models revealed substantial differences in the probability of developing advanced disease in the short and intermediate course of Crohn's disease, suggesting that a model-based prediction matrix is useful in early disease management.

Entities:  

Mesh:

Year:  2014        PMID: 24280875     DOI: 10.1097/01.MIB.0000436956.78220.67

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  19 in total

Review 1.  Oral pathology in inflammatory bowel disease.

Authors:  Miranda Muhvić-Urek; Marija Tomac-Stojmenović; Brankica Mijandrušić-Sinčić
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

2.  The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study.

Authors:  Johan Burisch; Daniel Bergemalm; Jonas Halfvarson; Viktor Domislovic; Zeljko Krznaric; Adrian Goldis; Jens F Dahlerup; Pia Oksanen; Pekka Collin; Luisa de Castro; Vicent Hernandez; Svetlana Turcan; Elena Belousova; Renata D'Incà; Alessandro Sartini; Daniela Valpiani; Martina Giannotta; Ravi Misra; Naila Arebi; Dana Duricova; Martin Bortlik; Kelly Gatt; Pierre Ellul; Natalia Pedersen; Jens Kjeldsen; Karina W Andersen; Vibeke Andersen; Konstantinos H Katsanos; Dimitrios K Christodoulou; Shaji Sebastian; Luisa Barros; Fernando Magro; Jóngerð Mm Midjord; Kári R Nielsen; Riina Salupere; Hendrika Al Kievit; Gediminas Kiudelis; Juozas Kupčinskas; Mathurin Fumery; Corinne Gower-Rousseau; Ioannis P Kaimakliotis; Doron Schwartz; Selwyn Odes; Laszlo Lakatos; Peter L Lakatos; Ebbe Langholz; Pia Munkholm
Journal:  United European Gastroenterol J       Date:  2020-07-26       Impact factor: 4.623

3.  Natural history of Crohn's disease following total colectomy and end ileostomy.

Authors:  Joanna Lopez; Gauree G Konijeti; Deanna D Nguyen; Jenny Sauk; Vijay Yajnik; Ashwin N Ananthakrishnan
Journal:  Inflamm Bowel Dis       Date:  2014-07       Impact factor: 5.325

Review 4.  The use of prognostic factors in inflammatory bowel diseases.

Authors:  Thomas Billiet; Marc Ferrante; Gert Van Assche
Journal:  Curr Gastroenterol Rep       Date:  2014-11

Review 5.  Evolving therapeutic goals in Crohn's disease management.

Authors:  Thomas Chateau; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2019-11-04       Impact factor: 4.623

6.  Impact of medical therapy on patients with Crohn's disease requiring surgical resection.

Authors:  Y T Nancy Fu; Thomas Hong; Andrew Round; Brian Bressler
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

7.  Health-related quality of life in inflammatory bowel disease in a European-wide population-based cohort 10 years after diagnosis.

Authors:  Gert Huppertz-Hauss; Marte Lie Høivik; Ebbe Langholz; Selwyn Odes; Milada Småstuen; Reinhold Stockbrugger; Geir Hoff; Bjørn Moum; Tomm Bernklev
Journal:  Inflamm Bowel Dis       Date:  2015-02       Impact factor: 5.325

8.  Crohn's Disease Clinical Network and Cohort (CONNECT) Study: The First Step Toward Nationwide Multicenter Research of Crohn's Disease in Korea.

Authors:  Jae Hee Cheon; You Sun Kim; Byong Duk Ye; Kang Moon Lee; Young Ho Kim; Joo Sung Kim; Dong Soo Han; Won Ho Kim
Journal:  Intest Res       Date:  2014-07

9.  Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease.

Authors:  Leonardo Guizzetti; Guangyong Zou; Reena Khanna; Parambir S Dulai; William J Sandborn; Vipul Jairath; Brian G Feagan
Journal:  J Crohns Colitis       Date:  2018-01-24       Impact factor: 9.071

Review 10.  Changing treatment paradigms for the management of inflammatory bowel disease.

Authors:  Jong Pil Im; Byong Duk Ye; You Sun Kim; Joo Sung Kim
Journal:  Korean J Intern Med       Date:  2017-12-28       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.